NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ANURAS · data 2026-10-30
Anupam Rasayan India Ltd.
In plain words
Price: 19.2% below its 52-week high of ₹1,415.
Delivery: 65.6% of traded shares were kept for delivery over the last 10 sessions, against 62.0% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,535 cr |
| Net profit (last 12 months) | ₹175 cr |
| Sales growth, 3 years (yearly) | 14.1% |
| Profit growth, 3 years (yearly) | -2.0% |
At a glance
P/E 74.4, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 5.5%, ROCE 9.0%, operating margin 15.7%: how much profit it earns on the money it uses.
Debt/equity 0.57, Profit growth -2.0% and sales growth 14.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (5.5%).
- Profit fell 2.0% a year over 3 years.
- Expensive on earnings (P/E 74.4).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
26/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 63.2% over the last 20 sessions vs 58.2% in the 40 before (1.09x); shares delivered per day 0.98x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹70.17 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 48/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Deal ● Dividend
- 27 Oct 26Insider SAST disclosure: Equity shares of Anupam Rasayan Ind… +1 acquired 90,67,215 shares +2.4% next session
- 8 Oct 26Insider SAST disclosure: Catalyst Trusteeship Limited acting… acquired 1,03,61,785 shares -2.8% next session
- 21 Sept 26Deal Bulk deal: ASHAPURA COMMODITIES sold ₹175.02 cr (net −₹70.17 cr) -0.8% next session
- 18 Sept 26Dividend Dividend ₹1.5 (ex-date) -1.7% next session
- 21 Jul 25Dividend Dividend ₹0.75 (ex-date) +0.5% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Anupam Rasayan India Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.57.
What is Anupam Rasayan India Ltd.'s P/E ratio?
About 74.4, based on the last 12 months' earnings and a price of ₹1,143.5 (data 2026-10-30).
What is the 52-week high and low of Anupam Rasayan India Ltd.?
The 52-week high is ₹1,415 and the 52-week low is ₹1,053.6.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Anupam Rasayan India Ltd. | ₹1,143.5 | ₹13,473 cr | 74.4 | — | 5.5% | 9% | 0.57 | +4.2% |
| NATCO Pharma Limited | ₹782.4 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -4.8% |
| Jubilant Pharmova Limited | ₹923.8 | ₹14,729 cr | 41.7 | — | 6% | 6.5% | 0.51 | -19.6% |
| Indegene Limited | ₹586.8 | ₹14,161 cr | 34.5 | 4.2 | 13.9% | 15.9% | 0.05 | +7.5% |
| Marksans Pharma Limited | ₹306.2 | ₹13,896 cr | 26.9 | — | 15.2% | 16.3% | 0.11 | +66.7% |
| Corona Remedies Limited | ₹2,149.6 | ₹13,125 cr | 66.1 | — | 27.4% | 32.4% | 0.22 | +46.2% |
Compare ANURAS with NATCOPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANURAS in NSE Scanner →